2021 Annual Meeting | C39 - Multiple Sclerosis Therapy: Disease-modifying Treatment

Date Monday 04/19/21

Time 08:00 AM - 09:00 AM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Jacqueline Bernard, MD, F�鶹��ýӳ��

Moderator(s) Nancy J. Newman, MD, F�鶹��ýӳ��

Topic(s) Multiple Sclerosis

Learning Objectives Participants should be comfortable with selecting DMTs based on risk stratification, including pregnancy and family planning for RRMS, SPMS, and PPMS; understand complications associated with approved DMTs in RRMS, SPMS, and PPMS; feel comfortable creating an algorithm for patients who break through therapies and no longer meet "NEDA" criteria; and provide updates on the impact of COVID-19 disease and vaccination on DMT doses.

CME Available 1.00 CME credit

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Introductory

Program Tracks Advanced Practice Provider

Recommended Audience Fellow, Resident, General Neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
08:00 AM - 08:50 AM EDT	Speaker	MS Therapy: Disease-modifying Treatment Jacqueline Bernard, MD, F�鶹��ýӳ��, Michael A. Lane, MD
08:50 AM - 09:00 AM EDT	Q&A	Live Q&A Jacqueline Bernard, MD, F�鶹��ýӳ��, Michael A. Lane, MD

Faculty Disclosures
Jacqueline Bernard, MD, F�鶹��ýӳ��	Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for 2ND MD. Dr. Bernard has received publishing royalties from a publication relating to health care.
Michael A. Lane, MD	Dr. Lane has nothing to disclose.
Nancy J. Newman, MD, F�鶹��ýӳ��	Dr. Newman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenSight. Dr. Newman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Chiesi. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Phelcom. The institution of Dr. Newman has received research support from GenSight. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care.